- Home
- NSSC vs TSHA Comparison
NSSC vs TSHA Comparison
Compare NSSC & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NSSC | TSHA |
|---|---|---|
| Founded | 1969 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.5B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | NSSC | TSHA |
|---|---|---|
| Price | $42.63 | $4.48 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 9 |
| Target Price | ★ $48.17 | $10.56 |
| AVG Volume (30 Days) | 478.9K | ★ 2.6M |
| Earning Date | 02-02-2026 | 02-25-2026 |
| Dividend Yield | ★ 1.40% | N/A |
| EPS Growth | ★ 0.75 | N/A |
| EPS | ★ 1.32 | N/A |
| Revenue | ★ $192,025,000.00 | $6,310,000.00 |
| Revenue This Year | $13.32 | N/A |
| Revenue Next Year | $9.84 | N/A |
| P/E Ratio | $32.59 | ★ N/A |
| Revenue Growth | ★ 2.94 | N/A |
| 52 Week Low | $19.00 | $1.05 |
| 52 Week High | $48.12 | $6.02 |
Technical Indicators
Market Signals| Indicator | NSSC | TSHA |
|---|---|---|
| Relative Strength Index (RSI) | 58.38 | 43.08 |
| Support Level | $41.71 | $4.40 |
| Resistance Level | $44.27 | $4.70 |
| Average True Range (ATR) | 1.68 | 0.25 |
| MACD | 0.54 | -0.00 |
| Stochastic Oscillator | 73.59 | 13.10 |
Price Performance
Historical ComparisonAbout NSSC NAPCO Security Technologies Inc.
NAPCO Security Technologies Inc manufactures security products, encompassing access control systems, door-locking products, intrusion and fire alarm systems and video surveillance products. Its products are used for various applications which includes alarm systems like automatic communicators, combination control panels/digital communicators and digital keypad systems, fire alarm control panel and area detectors mainly used for commercial, residential, institutional, industrial and governmental uses. Geographically, the company derives a majority of its revenue from the United States.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.